- Taking direct aim at Martin Shkreli's Turing Pharmaceuticals, Express Scripts (NASDAQ:ESRX) and Imprimis Pharmaceuticals (NASDAQ:IMMY-OLD) partner up to offer patients a low-cost alternative to Turing's $750-per-pill Daraprim (pyrimethamine).
- Imprimis is offering a compounded oral formulation of pyrimethamine and leucovorin (a form of folic acid) for $1 per capsule for people whose pharmacy benefit is managed by Express Scripts. Prescriptions will be processed starting this week.
- Mr. Shkreli earned pariah status in the pharmaceutical world with his aggressive price hike of Daraprim. He bought the rights to the 60-year old drug for $55M from Impax Laboratories (IPXL) and then immediately raised the price from ~$1 per pill to $750 per pill.
- IMMY is up 21% premarket on light volume.
- Previously: Imprimis Pharma fills the Daraprim price void with low cost formulation; shares up 26% premarket (Oct. 23)
- Previously: Turing's Shkreli bows to pressure and drops price of Daraprim (Sept. 23)